Appco Pharma LLC Recalls Prazosin Hydrochloride Capsules Over Nitrosamine Impurity, Signaling Recurring cGMP Challenges
Appco Pharma LLC has initiated a Class II recall for 88,008 bottles of Prazosin Hydrochloride Capsules due to N-nitroso-prazosin impurity C (NNP) exceeding acceptable limits. This firm-initiated action, stemming from cGMP deviations at their Piscataway, NJ facility, impacts U.S. nationwide distribution. This event underscores a concerning pattern of quality control issues for Appco Pharma, demanding immediate supply chain risk assessment.
FDA Mandates Class II Recall for Appco Pharma's Prazosin Hydrochloride Due to Nitrosamine Contamination
Appco Pharma LLC, based in Piscataway, New Jersey, has initiated a Class II voluntary recall (D-0419-2026) for 88,008 bottles of Prazosin Hydrochloride Capsules, USP, 1mg, 100-count. This significant action, commenced on March 27, 2026, stems from critical cGMP deviations, specifically the detection of N-nitroso-prazosin impurity C (NNP) at levels exceeding established acceptable limits. The affected product, manufactured by Appco Pharma LLC for Biocon Pharma Inc., Iselin, NJ, was distributed nationwide across the U.S. This recall impacts seven distinct lots, with expiration dates ranging from March 2026 to June 2027, highlighting a systemic issue rather than an isolated batch problem. For procurement directors, this means an immediate disruption to the supply of a critical medication used for hypertension and off-label for PTSD. Regulatory affairs heads must recognize the FDA's heightened scrutiny on nitrosamine impurities, which necessitates a thorough review of all active pharmaceutical ingredients (APIs) and finished drug products for similar risks. Business development executives should anticipate market shifts as healthcare providers and pharmacies seek alternative sources for Prazosin Hydrochloride.
Appco Pharma LLC's Piscataway Facility Under Scrutiny for Quality Control Failures
The recall of Prazosin Hydrochloride Capsules originates from Appco Pharma LLC's manufacturing site in Piscataway, New Jersey, United States. This facility is identified as a formulation site within the ChemLifeIntel knowledge graph, indicating its role in producing finished dosage forms. While the specific FEI number for this site is not publicly detailed in the recall notice, its operational integrity is now under significant question. The fact that the product is 'Manufactured for: Biocon Pharma Inc., Iselin, NJ' underscores the broader supply chain implications, as Appco Pharma serves as a contract manufacturer or primary supplier for other entities. For supply chain VPs, this event necessitates a comprehensive audit of all products sourced from Appco Pharma LLC's Piscataway facility, extending beyond Prazosin Hydrochloride. The consistent nature of the cGMP deviation, specifically related to impurity control, suggests potential systemic issues in their quality management systems. This could impact the availability and regulatory standing of other molecules such as Doxepin Hydrochloride or Clomiphene, which are also associated with Appco Pharma in our intelligence. Procurement teams must assess their exposure across their entire portfolio linked to this manufacturing site.
Supply Chain Exposure: Prazosin Hydrochloride Market Impact and Downstream Risks
The recall of 88,008 bottles of Prazosin Hydrochloride Capsules, USP, 1mg, represents a tangible supply disruption for a medication critical in managing hypertension and certain off-label conditions like PTSD. Prazosin Hydrochloride, an alpha-1 blocker, is a widely prescribed generic drug. The U.S.A. nationwide distribution pattern means that the impact will be felt across the entire American healthcare system, from major hospital networks to local pharmacies. Biocon Pharma Inc., as the marketer, faces immediate commercial repercussions, including potential loss of market share and reputational damage. For procurement directors, this event mandates an urgent review of current Prazosin Hydrochloride stock levels and consumption rates to predict potential shortages. Regulatory affairs heads must advise their organizations on the implications of sourcing from manufacturers with nitrosamine impurity issues, as regulatory bodies are increasingly stringent. Business development executives should identify opportunities to fill potential supply gaps, but also recognize the heightened regulatory bar for entry. The broader industry must internalize that nitrosamine contamination is not an isolated issue for specific molecules but a pervasive risk requiring vigilant control across diverse chemical syntheses.
Strategic Sourcing: Identifying Alternative Suppliers for Prazosin Hydrochloride
To mitigate the immediate and long-term supply risks associated with Appco Pharma LLC's Prazosin Hydrochloride recall, procurement teams must proactively explore alternative sourcing options. Our intelligence identifies several potential alternative suppliers with established presences in the pharmaceutical sector. These include Advagen Pharma, Burel Pharmaceuticals, Qingdao Biopeptek, Alembic Pharmaceuticals, Ajanta Pharma, DARMERICA, Amneal Pharmaceuticals NY, and SCH Global Services. Notably, Ajanta Pharma has a significant manufacturing footprint in India, while Amneal Pharmaceuticals NY operates within the United States, offering geographic diversity which is crucial for supply chain resilience. Procurement directors should prioritize initiating qualification processes with these alternative suppliers, understanding that such processes can range from 6 to 12 months depending on the complexity of the API and regulatory requirements. Regulatory affairs teams must ensure that any new supplier meets stringent cGMP standards and has robust controls for nitrosamine impurities. Diversifying the supplier base for Prazosin Hydrochloride and other critical generic drugs is no longer merely a best practice but an imperative to safeguard patient access and maintain business continuity.
Appco Pharma LLC's Recurring Regulatory Non-Compliance: A Pattern of Risk
This Prazosin Hydrochloride recall is not an isolated incident but rather indicative of a concerning pattern in Appco Pharma LLC's regulatory compliance history. Our intelligence reveals two prior significant Class II recalls. On January 15, 2020, Appco Pharma faced an FDA Class II recall for its Ranitidine Capsules, also due to NDMA impurity and cGMP failures. More recently, on January 29, 2025, the company initiated a recall for Venlafaxine, again signaling recurring quality control challenges. This history of repeated cGMP deviations and nitrosamine-related impurity issues strongly suggests systemic deficiencies in Appco Pharma's quality management systems rather than isolated manufacturing errors. For regulatory affairs heads, this pattern elevates the risk profile of any product associated with Appco Pharma LLC, necessitating enhanced due diligence and potentially more frequent audits. Supply chain VPs must recognize that relying on a manufacturer with such a track record introduces significant operational and reputational risk. This trend indicates that previous corrective actions may have been insufficient or inadequately implemented, suggesting a higher likelihood of future compliance issues and potential for escalated FDA enforcement actions.
Remediation Pathways and Anticipated FDA Scrutiny for Appco Pharma LLC
The ongoing Class II recall for Prazosin Hydrochloride Capsules requires Appco Pharma LLC to implement comprehensive corrective and preventive actions (CAPA) to address the root cause of the N-nitroso-prazosin impurity C (NNP) and associated cGMP deviations. The FDA will closely monitor the effectiveness of the recall and Appco's remediation efforts. This typically involves identifying the source of the nitrosamine impurity – whether from raw materials, manufacturing processes, or degradation pathways – and implementing robust controls, including updated analytical methods and process validation. Failure to adequately address these issues could lead to further regulatory actions, such as additional Warning Letters, an Import Alert if international supply chains are involved, or even a consent decree, which would severely restrict their operations. For business development executives, this situation creates uncertainty regarding Appco Pharma LLC's long-term viability as a reliable supplier. Procurement directors should demand transparent and detailed updates on Appco's remediation plan, considering independent third-party audits to verify compliance. Regulatory affairs teams must prepare for potentially prolonged supply disruptions and increased compliance burdens if their organizations continue to source from Appco Pharma LLC, given the company's demonstrated history of recurring quality issues.